Department of Medical Oncology, Santa Chiara Hospital, Largo Medaglie d'Oro, 38122, Trento, Italy.
Department of Radiological, Oncological & Anatomo-Pathological Sciences, La Sapienza University, Viale del Policlinico 155, 00161, Rome, Italy.
Future Oncol. 2021 Mar;17(7):807-815. doi: 10.2217/fon-2020-0391. Epub 2021 Jan 29.
Radium 223 (RA223) is currently administered as part of a therapeutic sequence with the other life-prolonging agents (LPAs) for metastatic castration-resistant prostate cancer (mCRPC). We retrospectively reviewed the clinical records of patients who had received at least three LPAs including RA223. Median overall survival (OS) from the start of first-line treatment was 39.8 months, with the patients who completed all six planned courses of RA223 having a longer OS than those who did not (53.2 vs 29.5 months; p < 0.0001). Our study confirms the activity of RA223 regardless of the treatment line in which it is administered and suggests that patient selection plays a central role in maximizing this activity.
镭 223（RA223）目前作为其他延长生命药物（LPAs）的治疗方案的一部分，用于治疗转移性去势抵抗性前列腺癌（mCRPC）。我们回顾性分析了至少接受三种 LPA 治疗（包括 RA223）的患者的临床记录。从一线治疗开始的中位总生存期（OS）为 39.8 个月，完成所有六周期 RA223 计划治疗的患者 OS 长于未完成的患者（53.2 个月 vs 29.5 个月；p<0.0001）。本研究证实了 RA223 的活性，无论其在治疗线中的位置如何，并表明患者选择在最大限度地发挥这种活性方面起着核心作用。
